Total Debt to Capital: Incyte (INCY)

This chart of the total debt-to-equity ratio demonstrates the financial stability of Incyte Corporation (INCY), where the value is maintained at 0.01. Stability is supported by a neutral geopolitical backdrop and the unrestricted export of pharmaceuticals. Risks are minimized by a balance between dermatology and oncology, as well as the development of treatments for inflammatory pathologies, which reduces dependence on a single drug.

The debt_total_eq_co ratio measures the proportion of borrowed funds relative to equity, determining financial leverage and the extent of the business's dependence on creditors. By analyzing the ratio of debt to equity, an investor assesses debt service risks. For Incyte Corporation (INCY), with its strong positions in oncology, this balance is critical when financing costly research and development. Stable dynamics of this metric confirm the issuer's solvency. Low leverage guarantees the company's stability during the rollout of new drugs.